During SOHO 2019 in Houston, US, Dr Jennifer A. Woyach from The Ohio State University (OSUCCC) in Columbus, US, spoke to the Lymphoma Hub about novel targeted therapies for chronic lymphocytic leukemia (CLL) treatment. She gives an overview of small molecule inhibitors of BTK in clinical development, other than ibrutinib, and venetoclax. Those include new covalent and reversible inhibitors, which are more selective and therefore associated with less toxicity but are also able to overcome ibrutinib resistance.
chronic lymphocytic leukemia,CLL,Lymphoma Hub,SOHO2019,Jennifer A Woyach,
During SOHO 2019 in Houston, US, Dr Jennifer A. Woyach from The Ohio State University (OSUCCC) in Columbus, US, spoke to the Lymphoma Hub about novel targeted therapies for chronic lymphocytic leukemia (CLL) treatment. She gives an overview of small molecule inhibitors of BTK in clinical development, other than ibrutinib, and venetoclax. Those include new covalent and reversible inhibitors, which are more selective and therefore associated with less toxicity but are also able to overcome ibrutinib resistance.
0 Comments